Company Description
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.
It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI.
The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.
Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Richard Paolone |
Contact Details
Address: 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 United States | |
| Phone | 561 589 7020 |
| Website | enterothera.com |
Stock Details
| Ticker Symbol | ENTO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604191 |
| ISIN Number | US33749P4081 |
| Employer ID | 46-4993860 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Joel Paolone | Chief Executive Officer and Director |
| Anna Skowron | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | 8-K | Current Report |
| Jul 8, 2025 | 8-K | Current Report |
| Jul 2, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 2, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 23, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 10, 2025 | SCHEDULE 13D/A | Filing |
| Jun 9, 2025 | SCHEDULE 13D | Filing |
| Jun 5, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 4, 2025 | DEF 14A | Other definitive proxy statements |